Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,039 | -39,754 | -29,513 | -20,430 | -13,448 |
| Depreciation Amortization | 1 | 4 | 3 | 2 | 1 |
| Other Working Capital | 2,494 | 699 | 29 | -2,209 | 3,991 |
| Other Operating Activity | 2,455 | -704 | -1,956 | -2,534 | -924 |
| Operating Cash Flow | $-6,089 | $-39,755 | $-31,437 | $-25,171 | $-10,380 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -10 | -11 | -6 | -3 |
| Investing Cash Flow | $-4 | $-10 | $-11 | $-6 | $-3 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 10,020 | N/A | N/A | N/A |
| Debt Repayment | N/A | -518 | N/A | -518 | N/A |
| Common Stock Issued | 2,545 | 22,712 | 22,610 | 22,638 | 22,980 |
| Other Financing Activity | 0 | 0 | -518 | 0 | 0 |
| Financing Cash Flow | $2,545 | $32,214 | $22,092 | $22,120 | $22,980 |
| Beginning Cash Position | 20,054 | 27,605 | 27,605 | 27,605 | 27,605 |
| End Cash Position | 16,506 | 20,054 | 18,249 | 24,548 | 40,202 |
| Net Cash Flow | $-3,548 | $-7,551 | $-9,356 | $-3,057 | $12,597 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,089 | -39,755 | -31,437 | -25,171 | -10,380 |
| Capital Expenditure | -4 | -10 | -11 | -6 | -3 |
| Free Cash Flow | -6,093 | -39,765 | -31,448 | -25,177 | -10,383 |